EPHX2 and neoplasm: Based on the data of our pilot study (Leineweber et al., 2020), we hypothesized that sorafenib treatment, due to sEH-inhibitory and possibly CYP-modulating effects, might increase the presence of potentially tumor growth-suppressing DHA-derived EDPs, as well as of potentially tumor growth-promoting EETs.